The DOI matches its Crossref record; 323 of the 323 references it cites were found in a registry or an index.
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Dementia Praecox and Paraphrenia.
(1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-6-1058_8 · Cited by 2,901
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,343
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research
(1994) · doi:10.17226/2139 · Cited by 2,073
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
(2009) · Cited by 2,013
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Influence of Family Life on the Course of Schizophrenic Disorders: A Replication
Brown, G. W., Birley, J. L. T., & Wing, J. K. (1972) · British Journal of Psychiatry · doi:10.1192/bjp.121.3.241 · Cited by 1,770
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,348
Perkins, D. O., Gu, H., Boteva, K., & Lieberman, J. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,346
Deficit and nondeficit forms of schizophrenia: the concept
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,332
The NIMH-MATRICS Consensus Statement on Negative Symptoms
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., & Marder, S. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj053 · Cited by 1,311
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
(2006) · Europe PMC (PubMed Central) · Cited by 1,299
A Meta-Analysis of Cognitive Remediation in Schizophrenia
McGurk, S. R., Twamley, E. W., Sitzer, D. I., McHugo, G. J., & Mueser, K. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07060906 · Cited by 1,214
Atypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research
Novins, D. K. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199503000-00028 · Cited by 1,076
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
McGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.921 · Cited by 1,056
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Wykes, T., Steel, C., Everitt, B., & Tarrier, N. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm114 · Cited by 1,029
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,027
Self-citationMcEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“In comparison to the 51 firstgeneration antipsychotic medications (FGAs), the class of 13 second-generation agents (SGAs) is believed to be associated with a lower risk of EPS but a higher risk of metabolic adverse effects (Allison et al., 1999; Meyer and Koro, 2004; Miyamoto et al., 2005; Kane, 2006; Crossley et al.,…”
ResultDe Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
Marwaha, S., & Johnson, S. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0762-4 · Cited by 922
Hogarty, G. E. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800070019003 · Cited by 917
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
PILLING, S., BEBBINGTON, P., KUIPERS, E., GARETY, P., GEDDES, J., ORBACH, G., & MORGAN, C. (2002) · Psychological Medicine · doi:10.1017/s0033291702005895 · Cited by 887
Duration of psychosis and outcome in first-episode schizophrenia
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1183 · Cited by 880
Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Glassman, A. H., & Bigger, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1774 · Cited by 822
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Neuroleptics and the Natural Course of Schizophrenia
Wyatt, R. J. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.325 · Cited by 787
The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements
Dixon, L. B., Dickerson, F., Bellack, A. S., Bennett, M., Dickinson, D., Goldberg, R. W., Lehman, A., Tenhula, W. N., Calmes, C., Pasillas, R. M., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp115 · Cited by 774
Early intervention in psychosis. The critical period hypothesis.
Birchwood, M. J., Todd, P., & Jackson, C. (1998) · PubMed · Cited by 756
Morrison, A. P., French, P., Walford, L., Lewis, S. W., Kilcommons, A., Green, J., Parker, S., & Bentall, R. P. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.4.291 · Cited by 740
Family intervention for schizophrenia
Pharoah, F., Mari, J., Rathbone, J., & Wong, W. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000088.pub2 · Cited by 737
Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology
TANDON, R., KESHAVAN, M., & NASRALLAH, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.011 · Cited by 720
Self-citationDo Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Early intervention in psychosis: The critical period hypothesis
Birchwood, M., Todd, P., & Jackson, C. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297663 · Cited by 681
Pitschel-Walz, G., Leucht, S., Bauml, J., Kissling, W., & Engel, R. R. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006861 · Cited by 648
Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Breier, A. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810270051007 · Cited by 626
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620
Multiple-Family Groups and Psychoeducation in the Treatment of Schizophrenia
McFarlane, W. R. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950200069016 · Cited by 560
McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.790 · Cited by 556
Folsom, D. P., Hawthorne, W., Lindamer, L., Gilmer, T., Bailey, A., Golshan, S., Garcia, P., Unützer, J., Hough, R., & Jeste, D. V. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.370 · Cited by 551
Early intervention for psychosis
Marshall, M., & Rathbone, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004718.pub3 · Cited by 531
Leucht, S., Barnes, T. R. E., Kissling, W., Engel, R. R., Correll, C., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1209 · Cited by 517
From dopamine to salience to psychosis—Linking biology, pharmacology and phenomenology of psychosis
Kapur, S., Mizrahi, R., & Li, M. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.01.003 · Cited by 512
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A. E., Michael, E., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050756 · Cited by 478
Wyatt, R. J., Alexander, R. C., Egan, M. F., & Kirch, D. G. (1988) · Schizophrenia Research · doi:10.1016/0920-9964(88)90034-5 · Cited by 477
Predictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Bilder, R., Goldman, R., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.544 · Cited by 466
Insel, T. R. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.540 · Cited by 459
MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA
Johnstone, E., Frith, C. D., Crow, T. J., Carney, M. W. P., & Price, J. S. (1978) · The Lancet · doi:10.1016/s0140-6736(78)90193-9 · Cited by 458
Time Course and Biologic Correlates of Treatment Response in First-Episode Schizophrenia
Lieberman, J. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820170047006 · Cited by 442
Psychiatric Symptoms and Quality of Life in Schizophrenia: A Meta-Analysis
Eack, S. M., & Newhill, C. E. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl071 · Cited by 437
Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 435
Using Neuroplasticity-Based Auditory Training to Improve Verbal Memory in Schizophrenia
Fisher, M., Holland, C., Merzenich, M. M., & Vinogradov, S. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08050757 · Cited by 426
A Meta-Analysis of Controlled Research on Social Skills Training for Schizophrenia
Kurtz, M. M., & Mueser, K. T. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.76.3.491 · Cited by 425
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Marder, S. R., & Fenton, W. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.010 · Cited by 421
Schizophrenia, “Just the Facts”: What we know in 2008
Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.022 · Cited by 409
Self-citationDelayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408
The effects of antipsychotic therapy on serum lipids: a comprehensive review
Meyer, J. M., & Koro, C. E. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.014 · Cited by 407
The Psychosocial Treatment of Schizophrenia: An Update
Bustillo, J. R., Lauriello, J., Horan, W. P., & Keith, S. J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.163 · Cited by 407
Efficacy of Psychological Therapy in Schizophrenia: Conclusions From Meta-analyses
Pfammatter, M. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl030 · Cited by 401
Goldberg, T. E., Goldman, R. S., Burdick, K. E., Malhotra, A. K., Lencz, T., Patel, R. C., Woerner, M. G., Schooler, N. R., Kane, J. M., & Robinson, D. G. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1115 · Cited by 394
Kapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
Cognitive therapy for psychosis in schizophrenia: An effect size analysis
Gould, R. A., Mueser, K. T., Bolton, E., Mays, V., & Goff, D. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00145-6 · Cited by 389
Cognitive-behavioral therapy for schizophrenia: An empirical review
RECTOR, N. A., & BECK, A. T. (2001) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200105000-00002 · Cited by 387
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387
Tiihonen, J., Walhbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. (2006) · BMJ · doi:10.1136/bmj.38881.382755.2f · Cited by 385
Improving Employment Outcomes for Persons With Severe Mental Illnesses
Lehman, A. F., Goldberg, R., Dixon, L. B., McNary, S., Postrado, L., Hackman, A., & McDonnell, K. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.2.165 · Cited by 377
Zimmermann, G., Favrod, J., Trieu, V. H., & Pomini, V. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.018 · Cited by 371
Kiss, B., Horváth, A., Némethy, Z., Schmidt, É., Laszlovszky, I., Bugovics, G., Fazekas, K., Hornok, K., Orosz, S., Gyertyán, I., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160432 · Cited by 367
Neuroplasticity of Neocortical Circuits in Schizophrenia
Lewis, D. A., & González-Burgos, G. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301563 · Cited by 365
Eack, S. M., Hogarty, G. E., Cho, R. Y., Prasad, K. M. R., Greenwald, D. P., Hogarty, S. S., & Keshavan, M. S. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.63 · Cited by 360
Self-citationWahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.990 · Cited by 357
Electroconvulsive therapy for schizophrenia
Tharyan, P., & Adams, C. E. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000076.pub2 · Cited by 354
Schizophrenia, “just the facts”: What we know in 2008Part 3: Neurobiology
KESHAVAN, M., TANDON, R., BOUTROS, N., & NASRALLAH, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.020 · Cited by 347
Self-citationBurns, T., Catty, J., Dash, M., Roberts, C., Lockwood, A., & Marshall, M. (2007) · BMJ · doi:10.1136/bmj.39251.599259.55 · Cited by 343
A Review of Cognitive Training in Schizophrenia
Twamley, E. W., Jeste, D. V., & Bellack, A. S. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007011 · Cited by 335
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Conn, P. J., Lindsley, C. W., & Jones, C. K. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.006 · Cited by 330
Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328
Kane (2003) · The Journal of Clinical Psychiatry · Cited by 323
PILLING, S., BEBBINGTON, P., KUIPERS, E., GARETY, P., GEDDES, J., MARTINDALE, B., ORBACH, G., & MORGAN, C. (2002) · Psychological Medicine · doi:10.1017/s0033291702005640 · Cited by 321
Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W. W., Keefe, R. S., Boter, H., Keet, I. P. M., Prelipceanu, D., Rybakowski, J. K., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08060806 · Cited by 320
Lynch, D., Laws, K. R., & McKenna, P. J. (2010) · Psychological Medicine · doi:10.1017/s003329170900590x · Cited by 317
LINCOLN, T., WILHELM, K., & NESTORIUC, Y. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.07.022 · Cited by 317
Introduction: Methods, Commentary, and Summary
Alexopoulos, G. S., Streim, J. E., Carpenter, D. P., & Docherty, J. P. (2004) · The Journal of Clinical Psychiatry · Cited by 316
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315
Cognitive Remediation in Schizophrenia
Medalia, A., & Choi, J. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9097-y · Cited by 315
Mishara, A. L., & Goldberg, T. E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.027 · Cited by 310
Intervention in Individuals at Ultra-High Risk for Psychosis: A Review and Future Directions
McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G., Riecher-Rössler, A., Klosterkötter, J., Ruhrmann, S., Schultze-Lutter, F., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04472 · Cited by 305
Self-citationTarrier, N., & Wykes, T. (2004) · Behaviour Research and Therapy · doi:10.1016/j.brat.2004.06.020 · Cited by 304
Garety, P. A., Fowler, D. G., Freeman, D., Bebbington, P., Dunn, G., & Kuipers, E. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.043570 · Cited by 296
Outcome of common mental disorders in Harare, Zimbabwe
Patel, V., Todd, C., Winston, M., Simunyu, E., Gwanzura, F., Acuda, W., & Mann, A. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.172.1.53 · Cited by 293
Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., & Friedman, J. H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 292
Towards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 291
Self-citationSwartz, M. S., Perkins, D. O., Stroup, T. S., Davis, S. M., Capuano, G., Rosenheck, R. A., Reimherr, F., McGee, M. F., Keefe, R. S. E., McEvoy, J. P., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.428 · Cited by 291
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
Adams, C. E., Fenton, M. K. P., Quraishi, S., & David, A. S. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.4.290 · Cited by 288
Roles of the Akt/GSK-3 and Wnt Signaling Pathways in Schizophrenia and Antipsychotic Drug Action
Freyberg, Z., Ferrando, S. J., & Javitch, J. A. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08121873 · Cited by 287
Psychosocial Treatment for First-Episode Psychosis: A Research Update
Penn, D. L., Waldheter, E. J., Perkins, D. O., Mueser, K. T., & Lieberman, J. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.12.2220 · Cited by 286
Schmidt, C. J., Chapin, D. S., Cianfrogna, J., Corman, M. L., Hajos, M., Harms, J. F., Hoffman, W. E., Lebel, L. A., McCarthy, S. A., Nelson, F. R., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132910 · Cited by 284
Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs
Grace, A. A., Bunney, B. S., Moore, H., & Todd, C. L. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10064-3 · Cited by 284
Important Issues in the Drug Treatment of Schizophrenia
Davis, J. M., Schaffer, C. B., Killian, G. A., Kinard, C., & Chan, C. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.1.70 · Cited by 284
Social skills training with schizophrenics: A meta-analytic evaluation.
Benton, M. K., & Schroeder, H. E. (1990) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.58.6.741 · Cited by 278
Tandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-Ibor, J. J., Okasha, A., Singh, B., Stein, D. J., Olie, J.-P., Fleischhacker, W. W., & Moeller, H.-J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.033 · Cited by 276
Self-citationSmith, M., Hopkins, D., Peveler, R. C., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 275
Phenothiazines and structurally related drugs
Crammer, J. L. (1975) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(75)90029-x · Cited by 274
Hogarty, G. E., Kornblith, S. J., Greenwald, D., DiBarry, A. L., Cooley, S., Ulrich, R. F., Carter, M., & Flesher, S. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1504 · Cited by 273
The history of clozapine and its emergence in the US market: a review and analysis
Crilly, J. (2007) · History of Psychiatry · doi:10.1177/0957154x07070335 · Cited by 272
Grauer, S. M., Pulito, V. L., Navarra, R. L., Kelly, M. P., Kelley, C., Graf, R., Langen, B., Logue, S., Brennan, J., Jiang, L., et al. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155994 · Cited by 269
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
Psychosocial Treatments to Promote Functional Recovery in Schizophrenia
Kern, R. S., Glynn, S. M., Horan, W. P., & Marder, S. R. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn177 · Cited by 267
An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings
Mari, J. D. J., & Streiner, D. L. (1994) · Psychological Medicine · doi:10.1017/s0033291700027720 · Cited by 266
Coldwell, C. M., & Bender, W. S. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.393 · Cited by 261
Harvey, P. D., & Bellack, A. S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn171 · Cited by 260
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl, S. M., Mignon, L., & Meyer, J. M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01334.x · Cited by 259
Freitas, C., Fregni, F., & Pascual-Leone, A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.027 · Cited by 251
Aleman, A., Sommer, I. E., & Kahn, R. S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0310 · Cited by 247
Adult Neurogenesis, Mental Health, and Mental Illness: Hope or Hype?: Figure 1.
Eisch, A. J., Cameron, H. A., Encinas, J. M., Meltzer, L. A., Ming, G.-L., & Overstreet-Wadiche, L. S. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3798-08.2008 · Cited by 247
Mauri, M. C., Volonteri, L. S., Colasanti, A., Fiorentini, A., De Gaspari, I. F., & Bareggi, S. R. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746050-00001 · Cited by 246
Álvarez-Jiménez, M., Parker, A. G., Hetrick, S. E., McGorry, P. D., & Gleeson, J. F. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp129 · Cited by 245
Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study
Coulter, D. M., Bate, A., Meyboom, R. H. B., Lindquist, M., & Edwards, I. R. (2001) · BMJ · doi:10.1136/bmj.322.7296.1207 · Cited by 234
Nelson, G., Aubry, T., & Lafrance, A. (2007) · American Journal of Orthopsychiatry · doi:10.1037/0002-9432.77.3.350 · Cited by 233
Lewis, D. A., & Sweet, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37335 · Cited by 233
Effect of second-generation antipsychotics on cognition: current issues and future challenges
Hill, S. K., Bishop, J. R., Palumbo, D., & Sweeney, J. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.143 · Cited by 233
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224 · cited 1×
“Recent studies on the impact of antipsychotic treatment on mortality in schizophrenia have yielded mixed results (Ren et al., 2009; Tiihonen et al., 2009a;Weinmann et al., 2009).”
ResultBenzodiazepines in the treatment of schizophrenia: a review and reappraisal
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.714 · Cited by 221
Who Benefits From Supported Employment: A Meta-analytic Study
Campbell, K., Bond, G. R., & Drake, R. E. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp066 · Cited by 219
Cornblatt, B. A., Lencz, T., Smith, C. W., Olsen, R., Auther, A. M., Nakayama, E., Lesser, M. L., Tai, J. Y., Shah, M. R., Foley, C. A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0410 · Cited by 218
Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended
Leucht, S., Busch, R., Hamann, J., Kissling, W., & Kane, J. M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.023 · Cited by 213
The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities
Carpenter, W. T., & Koenig, J. I. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301639 · Cited by 206
Verhoest, P. R., Chapin, D. S., Corman, M., Fonseca, K., Harms, J. F., Hou, X., Marr, E. S., Menniti, F. S., Nelson, F., O’Connor, R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900521k · Cited by 205
Volpi, S., Potkin, S. G., Malhotra, A. K., Licamele, L., & Lavedan, C. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04391 · Cited by 204
Cognitive Rehabilitation for Schizophrenia and the Putative Role of Motivation and Expectancies
Velligan, D. I., Kern, R. S., & Gold, J. M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj071 · Cited by 199
Greenhalgh, J., Knight, C., Hind, D., Beverley, C., & Walters, S. (2005) · Health Technology Assessment · doi:10.3310/hta9090 · Cited by 197
Negative symptoms of schizophrenia: a problem that will not go away
Stahl, S. M., & Buckley, P. F. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00947.x · Cited by 195 · cited 1×
“Whereas antipsychotics ameliorate negative symptoms linked with positive symptoms, they can worsen negative symptoms associated with extrapyramidal sideeffects (Carpenter et al., 1988; Stahl and Buckley, 2007).”
BackgroundNeuroleptic Withdrawal in Schizophrenic Patients
Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 195
Tiihonen, J., Wahlbeck, K., & Kiviniemi, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.01.002 · Cited by 194
Early intervention in psychosis
Singh, S. P. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.075804 · Cited by 194
Kinon, B. J., Chen, L., Ascher-Svanum, H., Stauffer, V. L., Kollack-Walker, S., Zhou, W., Kapur, S., & Kane, J. M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.164 · Cited by 182
EPS Profiles: The Atypical Antipsychotics
Weiden, P. J. (2007) · Journal of Psychiatric Practice · doi:10.1097/00131746-200701000-00003 · Cited by 177
Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders
Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061333 · Cited by 171
The 'atypicality' of antipsychotics: a concept re-examined and re-defined
Gründer, G., Hippius, H., & Carlsson, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2806 · Cited by 170
Benzodiazepines for schizophrenia
Dold, M., Li, C., Tardy, M., Khorsand, V., Gillies, D., & Leucht, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006391.pub2 · Cited by 169
Leach, K., Loiacono, R. E., Felder, C. C., McKinzie, D. L., Mogg, A., Shaw, D. B., Sexton, P. M., & Christopoulos, A. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.194 · Cited by 167
A Randomized, Controlled Trial of Computer-Assisted Cognitive Remediation for Schizophrenia
Dickinson, D., Tenhula, W. N., Morris, S. E., Brown, C., Peer, J. E., Spencer, K., Li, L., Gold, J. M., & Bellack, A. S. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020264 · Cited by 163
for the MEM-MD-29 Study Group, Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., & Gage, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.200 · Cited by 162
Time Course for Antipsychotic Treatment Response in First-Episode Schizophrenia
Emsley, R., Rabinowitz, J., & Medori, R. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.743 · Cited by 162
Dopamine D1receptor ligands: Where are we now and where are we going
Zhang, J., Xiong, B., Zhen, X., & Zhang, A. (2008) · Medicinal Research Reviews · doi:10.1002/med.20130 · Cited by 159
Assertive outreach for frequent users of psychiatric hospitals: A meta-analysis
Bond, G. R., McGrew, J. H., & Fekete, D. M. (1995) · The Journal of Mental Health Administration · doi:10.1007/bf02519193 · Cited by 158
Mojtabai, R., Fochtmann, L., Chang, S.-W., Kotov, R., Craig, T. J., & Bromet, E. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp045 · Cited by 158
Efficacy of atypicalv.typical antipsychotics in the treatment of early psychosis: meta-analysis
Crossley, N. A., Constante, M., McGuire, P. K., & Power, P. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.066217 · Cited by 157
Tai, S., & Turkington, D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp080 · Cited by 154 · cited 1×
“CBT seeks to help patients rationally appraise their experience of disease symptoms and how they respond to them, thereby reducing symptoms and preventing relapse (Turkington et al., 2008; Tai and Turkington, 2009).”
BackgroundNeuroleptic dysphoria: towards a new synthesis
Voruganti, L. N. P., & Awad, A. G. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1648-y · Cited by 153
Lange, J. J. D.-D., Knegtering, R., & Aleman, A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04808yel · Cited by 151
Family intervention in schizophrenia
Berglund, N., Vahlne †, J. O., & Edman, Å. (2003) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-003-0615-6 · Cited by 150
The American Psychiatric Press Textbook of Psychopharmacology
Schatzberg, A. F., & Nemeroff, C. B. (1995) · Medical Entomology and Zoology · Cited by 150
Barch, D. M., Carter, C. S., Arnsten, A. F. T., Buchanan, R. W., Cohen, J. D., Geyer, M. A., Green, M. F., Krystal, J. H., Nuechterlein, K. H., Robbins, T. W., et al. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn163 · Cited by 147
Rehabilitation for Adults with Severe Mental Illness and Substance Use Disorders
Lehman, A. F., Herron, J. D., Schwartz, R. P., & Myers, C. P. (1993) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199302000-00003 · Cited by 145
Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland
Durham, R., Chambers, J. A., Power, K., Sharp, D., Macdonald, R. R., Major, K., Dow, M., & Gumley, A. I. (2005) · Health Technology Assessment · doi:10.3310/hta9420 · Cited by 144
Zink, M., Englisch, S., & Meyer‐Lindenberg, A. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283366427 · Cited by 144
Charych, E. I., Liu, F., Moss, S. J., & Brandon, N. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.027 · Cited by 143
Outcomes of public concern in schizophrenia
Kooyman, I., Dean, K., Harvey, S., & Walsh, E. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.191.50.s29 · Cited by 142
Lurasidone: a new drug in development for schizophrenia
Meyer, J. M., Loebel, A. D., & Schweizer, E. E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903286388 · Cited by 141
Histamine H3and H4receptors as novel drug targets
Tiligada, E., Zampeli, E., Sander, K., & Stark, H. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903188438 · Cited by 141
A Survey of the Practice of Electroconvulsive Therapy in Asia
Chanpattana, W., Kramer, B. A., Kunigiri, G., Gangadhar, B. N., Kitphati, R., & Andrade, C. (2010) · Journal of Ect · doi:10.1097/yct.0b013e3181a74368 · Cited by 137
The case for long‐acting antipsychotic agents in the post‐CATIE era
Nasrallah, H. A. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00982.x · Cited by 136
Self-citationImplementing Evidence-Based Practices for People With Schizophrenia
Drake, R. E., Bond, G. R., & Essock, S. M. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp041 · Cited by 131
Adjunctive psychosocial therapies for the treatment of schizophrenia
Patterson, T. L., & Leeuwenkamp, O. R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.468 · Cited by 130
Swayze, V. W. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.505 · Cited by 130
Labrie, V., & Roder, J. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.002 · Cited by 129
Cognitive Function in Schizophrenia— Do Neuroleptics Make a Difference?
Mortimer, A. M. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00425-x · Cited by 129
Chien, W. T., Chan, S. W., & Thompson, D. R. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.008375 · Cited by 125
Pharmacogenomics in schizophrenia: the quest for individualized therapy
Basile, V. S., Masellis, M., Potkin, S. G., & Kennedy, J. L. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2517 · Cited by 125
Mikell, C. B., McKhann, G. M., Segal, S., McGovern, R. A., Wallenstein, M. B., & Moore, H. M. (2009) · Stereotactic and Functional Neurosurgery · doi:10.1159/000225979 · Cited by 124
Cited by
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Schmidt, S. J., Mueller, D. R., & Roder, V. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr079 · Cited by 461
Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies
van Kesteren, C. F. M. G., Gremmels, H., de Witte, L. D., Hol, E. M., Van Gool, A. R., Falkai, P. G., Kahn, R. S., & Sommer, I. E. C. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.4 · Cited by 368
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014) · BioMed Research International · doi:10.1155/2014/656370 · Cited by 327
Metadata
- Authors
- Tandon, R., Nasrallah, H. A., & Keshavan, M. S.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 122
- Issue
- 1-3
- Pages
- 1-23
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2139078690
- Cited by
- 385
- References
- 323
- FWCI
- 20.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.